STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8
Clinical trials for STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost radiation for head and neck cancer
Disease control Recruiting nowThis early-phase trial is testing whether adding the experimental drug ipatasertib to standard chemotherapy and radiation can better control advanced head and neck cancer. About 46 adults with certain types of head and neck cancer will receive the combination to find the safest d…
Matched conditions: STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:16 UTC
-
Could a Two-Drug punch before surgery beat head and neck cancer?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside their usual treatment. The goal is to improve quality of life…
Matched conditions: STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated May 17, 2026 06:16 UTC